Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Sep 16:10:1010016.
doi: 10.3389/fped.2022.1010016. eCollection 2022.

Monitoring disease progression in childhood bronchiectasis

Affiliations
Review

Monitoring disease progression in childhood bronchiectasis

Kathryn A Ramsey et al. Front Pediatr. .

Abstract

Bronchiectasis (not related to cystic fibrosis) is a chronic lung disease caused by a range of etiologies but characterized by abnormal airway dilatation, recurrent respiratory symptoms, impaired quality of life and reduced life expectancy. Patients typically experience episodes of chronic wet cough and recurrent pulmonary exacerbations requiring hospitalization. Early diagnosis and management of childhood bronchiectasis are essential to prevent respiratory decline, optimize quality of life, minimize pulmonary exacerbations, and potentially reverse bronchial disease. Disease monitoring potentially allows for (1) the early detection of acute exacerbations, facilitating timely intervention, (2) tracking the rate of disease progression for prognostic purposes, and (3) quantifying the response to therapies. This narrative review article will discuss methods for monitoring disease progression in children with bronchiectasis, including lung imaging, respiratory function, patient-reported outcomes, respiratory exacerbations, sputum biomarkers, and nutritional outcomes.

Keywords: biomarkers; bronchiectasis; children; exacerbations; imaging; lung function; monitoring; symptoms.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

References

    1. Chang AB, Boyd J, Bell L, Goyal V, Masters IB, Powell Z, et al. . Clinical and research priorities for children and young people with bronchiectasis: an international roadmap. ERJ Open Res. (2021) 7:00122–2021. 10.1183/23120541.00122-2021 - DOI - PMC - PubMed
    1. Franks LJ, Walsh JR, Hall K, Morris NR. Measuring airway clearance outcomes in bronchiectasis: a review. Eur Respir Rev. (2020) 29:190161. 10.1183/16000617.0161-2019 - DOI - PMC - PubMed
    1. Murray MP, Turnbull K, Macquarrie S, Hill AT. Assessing response to treatment of exacerbations of bronchiectasis in adults. Eur Respir J. (2009) 33:312–8. 10.1183/09031936.00122508 - DOI - PubMed
    1. Abu Dabrh AM, Hill AT, Dobler CC, Asi N, Farah WH, Haydour Q, et al. . Prevention of exacerbations in patients with stable non-cystic fibrosis bronchiectasis: a systematic review and meta-analysis of pharmacological and non-pharmacological therapies. BMJ Evid Based Med. (2018) 23:96–103. 10.1136/bmjebm-2018-110893 - DOI - PubMed
    1. Lee E, Sol IS, Kim JD, Yang HJ, Min TK, Jang GC, et al. . Long-term macrolide treatment for non-cystic fibrosis bronchiectasis in children: a meta-analysis. Sci Rep. (2021) 11:24287. 10.1038/s41598-021-03778-8 - DOI - PMC - PubMed

LinkOut - more resources